<DOC>
	<DOCNO>NCT02178358</DOCNO>
	<brief_summary>The main purpose study evaluate safety effectiveness study drug know LY2157299 participant hepatocellular carcinoma .</brief_summary>
	<brief_title>A Study LY2157299 Participants With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Have histological evidence diagnosis HCC amenable curative surgery . Have ChildPugh Class A . Have presence measurable disease . Have adequate organ function . Have performance status ≤1 Eastern Cooperative Oncology Group ( ECOG ) scale . If male female reproductive potential , must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug . If female childbearing potential , must negative serum pregnancy test 7 day prior first dose study drug . Are able swallow capsule tablet . Have available diagnostic biopsy tumor tissue . Have receive previous systemic treatment advance disease . Have know HCC fibrolamellar mixed histology . Have presence clinically relevant ascites . Have liver transplant . Have moderate severe cardiac disease . Have active uncontrolled clinically serious hepatitis B virus hepatitis C virus infection . Have experience Grade 3 4 gastrointestinal bleeding variceal bleed episode 3 month prior enrollment require transfusion endoscopic operative intervention . Have esophageal gastric varix require immediate intervention represent high bleeding risk . Had major surgery within 4 week prior study randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>transform growth factor beta ( TGF-β )</keyword>
</DOC>